Tempus AI, Inc. — fact timeline

Tempus AI, Inc. shareholders voted on Non-Binding Advisory Vote on the Frequency of Stockholder Advisory Votes on the Compensation of the Company's Named Executive Officers at the 2026-05-21 meeting.

“Proposal 3. Non-Binding Advisory Vote on the Frequency of Stockholder Advisory Votes on the Compensation of the Company’s Named Executive Officers. The Company’s Class A stockholders and Class B stockholders, voting together as a single class, cast an advisory vote on the frequency of stockholder advisory votes on the compensation of the Company’s named executive officers. The final voting results are as follows: One Year Two Years Three Years Abstentions Broker Non-Votes 42,744,443 115,765 191,972,032 278,784 27,440,890”

Tempus AI, Inc. shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-05-21 meeting.

“Proposal 2. Ratification of the Appointment of Independent Registered Public Accounting Firm. The Company’s Class A stockholders and Class B stockholders, voting together as a single class, ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows: Votes For Votes Against Abstentions 262,396,207 90,662 65,045”

Tempus AI, Inc. shareholders approved Election of nine directors to serve until the 2027 Annual Meeting at the 2026-05-21 meeting.

“Proposal 1. Election of Directors. The Company’s Class A stockholders and Class B stockholders, voting together as a single class, elected the nine directors listed below, each to serve until the Company’s 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal. The final voting results are as follows: Name Votes For Votes Withheld Broker Non-Votes Eric Lefkofsky 226,135,852 8,975,172 27,440,890”

Tempus AI, Inc. entered into Indenture with U.S. Bank Trust Company, National Association valued at $460.0 million aggregate principal amount (effective 2026-05-12).

“On May 12, 2026, Tempus AI, Inc. (the “ Company ”) completed its previously announced private offering (the “ Offering ”) of $460.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032 (the “ Notes ”), including the exercise in full of the initial purchasers’ option to purchase up to an additional $60.0 million principal amount of the Notes. The Notes were issued pursuant to an indenture, dated May 12, 2026 (the “ Indenture ”), between the Company and U.S. Bank Trust Company, National Association, as trustee.”

Tempus AI, Inc. reported the quarter ended March 31, 2026 results: revenue $348.1 million, net income ($125.9 million), EPS ($0.70). Guidance raised.

“technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2026. • Revenue of $348.1 million, up 36.1% year-over-year • Diagnostics revenue of $261.1 million, representing 34.7% growth year-over-year, driven by Oncology volume growth of 28% • MRD volume was ~6,500 tests”

Tempus AI, Inc. incurred revolving credit of $100.0 million with Ares Capital Corporation at Term SOFR plus 3.75% maturing February 3, 2030.

“The Company borrowed $200.0 million in Third Amendment Term Loans and $100.0 million in Revolving Loans on the Closing Date to fund, in part, the consideration payable in connection with its acquisition of Ambry. The Third Amendment Term Loan Facility and the Priority ABL Facility mature on February 3, 2030.”

Tempus AI, Inc. incurred term loan of $200.0 million with Ares Capital Corporation at Term SOFR plus 7.25% cash (through Dec 31, 2025); thereafter Term SOFR plus 6.75 maturing February 3, 2030.

“The Company borrowed $200.0 million in Third Amendment Term Loans and $100.0 million in Revolving Loans on the Closing Date to fund, in part, the consideration payable in connection with its acquisition of Ambry. The Third Amendment Term Loan Facility and the Priority ABL Facility mature on February 3, 2030.”